A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
- Conditions
- Ataxia-TelangiectasiaAtaxia-Telangiectasia (A-T)
- Interventions
- Drug: N-Acetyl-L-LeucineOther: Placebo
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- IntraBio Inc
- Target Recruit Count
- 60
- Registration Number
- NCT06673056
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇨ðŸ‡University of Bern, Bern, Switzerland
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
- Conditions
- Niemann-Pick Disease, Type C
- Interventions
- Drug: N-Acetyl-L-LeucineOther: Placebo
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- IntraBio Inc
- Target Recruit Count
- 53
- Registration Number
- NCT05163288
- Locations
- 🇨🇿
First Faculty of Medicine, Charles University Hospital Prague, Praha, Czechia
🇩🇪University of Giessen, Gießen, Germany
🇳🇱Amsterdam UMC, Amsterdam, Netherlands
N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)
- Conditions
- Ataxia TelangiectasiaLouis Bar Syndrome
- Interventions
- Drug: IB1001
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- IntraBio Inc
- Target Recruit Count
- 39
- Registration Number
- NCT03759678
- Locations
- 🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇩🇪University of Giessen, Gießen, Germany
🇩🇪Ludwig Maximilian University of Munich, München, Germany
N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
- Conditions
- Sandhoff DiseaseGM2 GangliosidosisTay-Sachs Disease
- Interventions
- Drug: IB1001
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- IntraBio Inc
- Target Recruit Count
- 30
- Registration Number
- NCT03759665
- Locations
- 🇩🇪
Ludwig Maximilian University of Munich, München, Germany
🇩🇪University of Giessen, Gießen, Germany
🇪🇸Bellvitge University Hospital, Barcelona, Spain
N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)
- Conditions
- Niemann-Pick Disease, Type C
- Interventions
- Drug: IB1001
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- IntraBio Inc
- Target Recruit Count
- 33
- Registration Number
- NCT03759639
- Locations
- 🇸🇰
Comenius University in Bratislva, Bratislava, Slovakia
🇪🇸Bellvitge University Hospital, Barcelona, Spain
🇺🇸Mayo Clinic, Rochester, Minnesota, United States